LamdaGen
LamdaGen Corporation is dedicated to developing innovative plasmonic biosensor systems for rapid, high-sensitivity diagnostics across human, animal, food, water, and environmental health sectors. Their mission is to improve lives through advanced detection solutions that are fast, accurate, and globally accessible, utilizing their proprietary Plasmonic Amplification Technology (PAT) and the LAuRA platform to enable sensitive, rapid, and easy-to-use testing.
Industries
Nr. of Employees
small (1-50)
Products
Plasmonic rapid test system (reader and disposable cartridges)
Turnkey rapid testing system comprising disposable capillary-driven cartridges and a digital reader that images sensors and produces quantitative results in approximately 15 minutes; designed for compatibility with multiple sample types and for multiplexed target detection.
Plasmonic rapid test system (reader and disposable cartridges)
Turnkey rapid testing system comprising disposable capillary-driven cartridges and a digital reader that images sensors and produces quantitative results in approximately 15 minutes; designed for compatibility with multiple sample types and for multiplexed target detection.
Services
Licensing of plasmonic sensing technology and support services to integrate sensors and assays into partner R&D, services and commercial products.
Joint development projects and subcontracted studies to demonstrate assay performance for specific detection use cases, including government and commercial collaborations.
Licensing of plasmonic sensing technology and support services to integrate sensors and assays into partner R&D, services and commercial products.
Joint development projects and subcontracted studies to demonstrate assay performance for specific detection use cases, including government and commercial collaborations.
Expertise Areas
- Plasmonic biosensor development
- Point-of-care diagnostic development
- Immunoassay and enzymatic assay development
- Nano-structured thin-film fabrication
Key Technologies
- Localized Surface Plasmon Resonance (LSPR) sensors
- Nano-structured metallic thin-film fabrication
- Plasmonic signal amplification methods
- Rapid immunoassay formats (sandwich, competitive, enzymatic)
News & Updates
LamdaGen Corporation has entered into a subcontract with MRIGlobal and JPEO-CBRND to undertake proof-of-concept studies for the detection of a priority biothreat using immobilized phage receptor-binding proteins.
LamdaGen Corporation announced the formation of its Strategic Advisory Board with industry leaders in diagnostic innovation.
This brief describes the optical properties of LamdaGen’s gold plasmonic sensor surfaces compared to gold colloids, highlighting their superior biosensing capabilities.
LamdaGen received a patent grant from the Indian Patent Office for their enzymatic assay for LSPR, enhancing their diagnostic technology portfolio.
The USPTO has given official notice of allowance for LamdaGen’s patent on digital LSPR technology for enhanced assay sensitivity.
The Japanese Patent Office has given official notice of allowance for LamdaGen’s patent on mobile/wearable devices with LSPR sensors.
LamdaGen Corporation has entered into a subcontract with MRIGlobal and JPEO-CBRND to undertake proof-of-concept studies for the detection of a priority biothreat using immobilized phage receptor-binding proteins.
LamdaGen Corporation announced the formation of its Strategic Advisory Board with industry leaders in diagnostic innovation.
This brief describes the optical properties of LamdaGen’s gold plasmonic sensor surfaces compared to gold colloids, highlighting their superior biosensing capabilities.
LamdaGen received a patent grant from the Indian Patent Office for their enzymatic assay for LSPR, enhancing their diagnostic technology portfolio.
The USPTO has given official notice of allowance for LamdaGen’s patent on digital LSPR technology for enhanced assay sensitivity.
The Japanese Patent Office has given official notice of allowance for LamdaGen’s patent on mobile/wearable devices with LSPR sensors.